NewsMV
(Nasdaq: QNCX) announced a corporate transformation on October 9, 2026, changing its name to IRulya Therapeutics Inc.
This rebranding comes after the firm completed its merger with Orphai Therapeutics and closed a private placement that raised roughly $115 million in gross proceeds during May 2026.
IRulya’s common stock will begin trading on the Nasdaq Capital Market under the ticker “IRLA” effective October 12, 2026.
The company is shifting its focus to the clinical development of LAM-001, an investigational formulation of inhaled rapamycin.
Keep reading